GLP-1 (Glucagon-Like Peptide-1) is primarily produced in enteroendocrine L-cells located in the distal small intestine (ileum) and colon in response to eating
Reduces inflammation and oxidative stress: BPC157 appears to downregulate proinflammatory mediators and promote nitric oxide balance, which may help with chronic pain, arthritis, and fibromyalgia. Clinically, we use BPC157 as part of programs for: Tendon and ligament injuries Muscle strains and overuse injuries Gastrointestinal disorders like IBS, Crohns disease, ulcerative colitis, and reflux Leaky gut and systemic inflammation When combined in the Wolverine Stack, BPC157 tends to provide more localized repair at the site of injury and within the gut
Gestational diabetes mellitus Gestational diabetes mellitus class A1 Clinical Classification Clinical Classifications group individual ICD-10-CM diagnosis codes into broader, clinically meaningful categories
This is why the TGA undertakes post-market monitoring of all medicines, as well as other therapeutic goods, and encourages health professionals to report adverse events
